Sigrid Therapeutics secured investment capital of $8.4 million from a number of Sweden’s family offices

Sigrid Therapeutics, a Stockholm, Sweden-based clinical stage biotech company, announced that it raised funding in a capital raise round closed at $8.4 million.

The money was raised from a number of Sweden’s family offices including Hans and Barbara Bergström and the Mattsson family of Santa Maria fame, joined by investment company Crosslight Partners, Irish investment network Irrus Investments and US-based global VC fund Joyance Partners.

Sigrid Therapeutics, founded in 2014 and led by CEO Sana Alajmovic, has as lead product called SiPore15, an orally-administered medical device consisting of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in the gut. SiPore15 consists of precisely engineered micron-sized silica particles with tailored porosity capable of entrapping digestive enzymes inside the gut, lowering calorie uptake.

Sigrid previously raised around $9 million.